|Assessment Status||Assessment process complete|
|Indication||For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation|
|Rapid review commissioned||13/08/2012|
|Rapid review completed||22/08/2012|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
|Full pharmacoeconomic assessment commissioned by HSE||24/10/2012|
|NCPE assessment completed||21/01/2013|
|NCPE assessment outcome||Reimbursement not recommended at the submitted price|
21 January 2013
In view of the very high acquisition cost (€234,804 per patient per annum), the significant budget impact (approximately €28 million per annum) and the inability of the manufacturer to demonstrate cost-effectiveness the NCPE cannot recommend reimbursement of ivacaftor at the submitted price.
01 February 2013
The NCPE recommendation led to follow-up discussions between the HSE Corporate Pharmaceutical Unit and the company, Vertex Pharmaceuticals. Following these discussions a positive recommendation was made by the HSE Drugs Group, supporting the provision of ivacaftor (Kalydeco®) for Irish CF patients, whilst at the same time significantly reducing the budget impact of the drug.